VALN

Valneva SE Sponsored ADR (VALN) | Rumor.io

Valneva

VALN

Attention (50-day avg)0%

Attention rank (50-day avg)#2,613

Bullish sentiment (50-day avg)80%

Price to earnings ratio72.7

Market capitalization613.5M

Earnings per share-2.05

Dividend yield (TTM)—

Revenue (annual)174.7M

Net income (annual)-115.2M

Social

What share of all stock conversation is about VALN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% +0

Aug 14

The European Medicines Agency has validated the Marketing Authorization Application for Valneva's Lyme disease vaccine candidate, developed in partnership with Pfizer, based on the Phase 3 VALOR trial's favorable efficacy and safety results.
The vaccine candidate showed over 70% efficacy in the Phase 3 trial, with Pfizer and Valneva announcing the validation of their Marketing Authorization Application by the EMA.
Valneva's stock price surged by over 25% in pre-market trading, with the company's shares continuing to rise after the EMA's validation, following a successful Phase 3 trial for the Lyme disease vaccine candidate.

Generated by AI

Sentiment

Of the messages about VALN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +45	84.43% +0.39
Bearish	—	—	0% -45	15.57% -0.39

Bullish· Jun 21

Valneva SE is expected to receive EU approval for its COVID-19 vaccine and a 60 million dose order decision this week.
The company's Chikungunya vaccine has shown great phase 3 results and is awaiting FDA fast track approval.
Valneva SE has partnered with Pfizer on a Lyme disease vaccine, with Pfizer investing 8.1% of the company's capital to support the project.

Bearish· Jan 20

$VALN shorts are bailing out before the opening bell, trying to drop the price as fast as they can.
The market expects $VALN to reach average prices, but it has not even gotten close.
$VALN's price is undervalued at current levels, making it a risky buy despite shorts bailing out.

Generated by AI

Topics

Of the messages about VALN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	83.04%
Analysts	—	—	—	10.43%
Technical Analysis	—	—	—	1.74%
Controversies	—	—	—	1.3%
Earnings	—	—	—	3.48%
Macro	—	—	—	0%

Announcements· Aug 25

The FDA has suspended the license for Valneva's Chikungunya vaccine, IXCHIQ, in the U.S. due to four new serious adverse event reports consistent with chikungunya-like illness.
The suspension is effective immediately, requiring Valneva to stop shipping and selling the vaccine in the United States.
The FDA's decision is based on reports of serious adverse events, including 21 hospitalizations and 3 deaths, primarily in individuals aged 70-82.

Controversies· Sep 13

Valneva SE has received a termination notice from the UK Government for its COVID-19 vaccine supply agreement, citing a breach of contract.
The UK's decision to terminate the contract may be related to concerns over the vaccine's efficacy, as it reportedly performed less well than rivals in a recent UK trial.
Valneva has denied breaching the contract, and some analysts believe the UK may still need the vaccine to tackle variant issues, potentially leading to a large order.

Generated by AI

Community

Of the messages about VALN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	98.48%	96.43%	21.06%
Newcomers	100%	1.52%	3.57%	78.94%

Regulars· Feb 17

Valneva SE (VALN) announced that Pfizer has discontinued approximately half of the participants in the Phase 3 clinical trial evaluating Lyme disease vaccine candidate VLA15 due to Good Clinical Practice (GCP) violations by a third-party trial site sponsor.
The discontinuation of participants is expected to add significant time to the trial, and the issue is time-related, not safety-related, according to regular participants in the discussion.
Valneva SE's stock price (VALN) has taken a hit, dipping 10.47% after the announcement, with some participants speculating that the issue may be with the sponsor, Care Access.

Newcomers· Aug 14

Valneva's Lyme disease vaccine candidate has received validation from the European Medicines Agency, a key regulatory milestone for the company.
Pfizer and Valneva's joint vaccine application has been accepted, with the Phase 3 VALOR trial showing favorable efficacy and safety results.
The stock price of Valneva has surged over 26% after the validation, with investors showing enthusiasm for the company's clinical portfolio.

Generated by AI

News

Valneva (VALN) Gets a Buy from H.C. Wainwright

Detailed price information for Valneva Se ADR (VALN-Q) from The Globe and Mail including charting and trades.

7d agoThe Globe and Mail

Pfizer (PFE), Valneva (VALN) Lyme Vaccine Moves to EMA Review Despite Phase 3 Caveat

Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN) reported on August 14 that the European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, the companies’ experimental Lyme disease vaccine candidate, and will now begin the official review. For a vaccine candidate first proposed in a 2020 collaboration deal between Pfizer Inc. (NYSE:PFE) and French […]

14d agoYahoo Finance

Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva

Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Vaccines Market Distribution by Type of Vaccine API, Targeted Patient Population, Type of Vaccines, Route of Administration, and Key Geographical Region - Trends and Forecasts Till 2035" has been added to ResearchAndMarkets.com's offering. The global vaccines market is projected to increase from approximately USD 48 billion to USD 94 billion by 2030, representing a compound annual growth rate of about 11.9% during the forecast period. Market expans

23d agoYahoo Finance UK

Pfizer (PFE) Starts EMA Review For Its Lyme Disease Vaccine

Pfizer (NYSE:PFE) and Valneva announced that the European Medicines Agency has validated the Marketing Authorization Application for their Lyme disease vaccine candidate, PF-07307405. The validation starts the EMA regulatory assessment process for what could become a first in class Lyme disease vaccine for use in both North America and Europe. The application is supported by Phase 3 efficacy data, with the companies highlighting an unmet medical need in Lyme disease prevention. This move by...

1mo agoYahoo Finance

Valneva (VALN) Q2 2026 Earnings Call Transcript

Detailed price information for Valneva Se ADR (VALN-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Pfizer (PFE) Gets EMA Lyme Vaccine Filing Validation As ADC Patent Clout Grows

Pfizer (NYSE:PFE) and Valneva had their Marketing Authorization Application for a Lyme disease vaccine candidate validated by the European Medicines Agency, confirming it is ready for full review. The vaccine filing follows late stage clinical results that reported encouraging efficacy and safety in preventing Lyme disease. A recent patent report highlighted Pfizer as a leading holder of next generation antibody drug conjugate intellectual property in cancer treatment. For readers looking...

1mo agoYahoo Finance

Also Discussed

Investors talking about VALN also mention

#	Name	Attention
1	DVAX - Dynavax Technologies Corporation	——
2	CVAC - CureVac N.V.	——
3	Novavax Inc.NVAX	0.03%-0.01
4	Innate Pharma S.A. Sponsored ADRIPHA	0%0
5	AstraZeneca PLC American Depositary SharesAZN	0.02%+0.02
6	TBIO - Telesis Bio, Inc.	——
7	BioNTech SEBNTX	0%+0
8	Emergent BioSolutions Inc.EBS	0%new
9	GRTS - Gritstone bio, Inc.	——
10	Arbutus Biopharma CorporationABUS	0%0

Valneva SE Sponsored ADR

Healthcare
Biotechnology

Valneva SE Sponsored ADR is an American depositary receipt representing shares of Valneva SE, a specialty vaccine company focused on the development, manufacture, and commercialization of prophylactic vaccines for infectious diseases with unmet medical needs. Valneva’s current portfolio includes vaccines for travel and endemic disease prevention, serving public health, travel medicine, and infectious disease markets. The company works across research, clinical development, manufacturing, and commercialization, giving it an integrated role in bringing vaccines from development to market. Its business is centered on specialty immunization products designed for targeted patient groups and healthcare providers, with a focus on prevention rather than treatment. Valneva SE is headquartered in Saint-Herblain, France.

Website

Location

6 rue Alain Bombard

Saint-Herblain, 44800

France

Social

What share of all stock conversation is about VALN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% +0

Aug 14

The European Medicines Agency has validated the Marketing Authorization Application for Valneva's Lyme disease vaccine candidate, developed in partnership with Pfizer, based on the Phase 3 VALOR trial's favorable efficacy and safety results.
The vaccine candidate showed over 70% efficacy in the Phase 3 trial, with Pfizer and Valneva announcing the validation of their Marketing Authorization Application by the EMA.
Valneva's stock price surged by over 25% in pre-market trading, with the company's shares continuing to rise after the EMA's validation, following a successful Phase 3 trial for the Lyme disease vaccine candidate.

Generated by AI

Sentiment

Of the messages about VALN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +45	84.43% +0.39
Bearish	—	—	0% -45	15.57% -0.39

Bullish· Jun 21

Valneva SE is expected to receive EU approval for its COVID-19 vaccine and a 60 million dose order decision this week.
The company's Chikungunya vaccine has shown great phase 3 results and is awaiting FDA fast track approval.
Valneva SE has partnered with Pfizer on a Lyme disease vaccine, with Pfizer investing 8.1% of the company's capital to support the project.

Bearish· Jan 20

$VALN shorts are bailing out before the opening bell, trying to drop the price as fast as they can.
The market expects $VALN to reach average prices, but it has not even gotten close.
$VALN's price is undervalued at current levels, making it a risky buy despite shorts bailing out.

Generated by AI

Topics

Of the messages about VALN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	83.04%
Analysts	—	—	—	10.43%
Technical Analysis	—	—	—	1.74%
Controversies	—	—	—	1.3%
Earnings	—	—	—	3.48%
Macro	—	—	—	0%

Announcements· Aug 25

The FDA has suspended the license for Valneva's Chikungunya vaccine, IXCHIQ, in the U.S. due to four new serious adverse event reports consistent with chikungunya-like illness.
The suspension is effective immediately, requiring Valneva to stop shipping and selling the vaccine in the United States.
The FDA's decision is based on reports of serious adverse events, including 21 hospitalizations and 3 deaths, primarily in individuals aged 70-82.

Controversies· Sep 13

Valneva SE has received a termination notice from the UK Government for its COVID-19 vaccine supply agreement, citing a breach of contract.
The UK's decision to terminate the contract may be related to concerns over the vaccine's efficacy, as it reportedly performed less well than rivals in a recent UK trial.
Valneva has denied breaching the contract, and some analysts believe the UK may still need the vaccine to tackle variant issues, potentially leading to a large order.

Generated by AI

Community

Of the messages about VALN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	98.48%	96.43%	21.06%
Newcomers	100%	1.52%	3.57%	78.94%

Regulars· Feb 17

Valneva SE (VALN) announced that Pfizer has discontinued approximately half of the participants in the Phase 3 clinical trial evaluating Lyme disease vaccine candidate VLA15 due to Good Clinical Practice (GCP) violations by a third-party trial site sponsor.
The discontinuation of participants is expected to add significant time to the trial, and the issue is time-related, not safety-related, according to regular participants in the discussion.
Valneva SE's stock price (VALN) has taken a hit, dipping 10.47% after the announcement, with some participants speculating that the issue may be with the sponsor, Care Access.

Newcomers· Aug 14

Valneva's Lyme disease vaccine candidate has received validation from the European Medicines Agency, a key regulatory milestone for the company.
Pfizer and Valneva's joint vaccine application has been accepted, with the Phase 3 VALOR trial showing favorable efficacy and safety results.
The stock price of Valneva has surged over 26% after the validation, with investors showing enthusiasm for the company's clinical portfolio.

Generated by AI

Valneva

Social

Aug 14

Bullish· Jun 21

Bearish· Jan 20

Announcements· Aug 25

Controversies· Sep 13

Regulars· Feb 17

Newcomers· Aug 14

Valneva (VALN) Gets a Buy from H.C. Wainwright

Pfizer (PFE), Valneva (VALN) Lyme Vaccine Moves to EMA Review Despite Phase 3 Caveat

Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva

Pfizer (PFE) Starts EMA Review For Its Lyme Disease Vaccine

Valneva (VALN) Q2 2026 Earnings Call Transcript

Pfizer (PFE) Gets EMA Lyme Vaccine Filing Validation As ADC Patent Clout Grows

Also Discussed

Valneva SE Sponsored ADR

Company Information

Location

Valneva (VALN) Gets a Buy from H.C. Wainwright

Pfizer (PFE), Valneva (VALN) Lyme Vaccine Moves to EMA Review Despite Phase 3 Caveat

Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva

Pfizer (PFE) Starts EMA Review For Its Lyme Disease Vaccine

Valneva (VALN) Q2 2026 Earnings Call Transcript

Pfizer (PFE) Gets EMA Lyme Vaccine Filing Validation As ADC Patent Clout Grows

Also Discussed

Social

Aug 14

Bullish· Jun 21

Bearish· Jan 20

Announcements· Aug 25

Controversies· Sep 13

Regulars· Feb 17

Newcomers· Aug 14